INTRODUCTION: Because of the lack of published evidence, this study was done to explore the decisions and rationale of uro-oncology consultants regarding the treatment of @entity1 with @entity150 who have positive lymph nodes after radical cystectomy (RC) and neoadjuvant chemotherapy (NAC). MATERIALS AND METHODS: An electronic survey was sent to UK pelvic @entity5 centers regarding: (1) choice of NAC regimen; (2) indications for reimaging; (3) choice and indication of adjuvant chemotherapy (AC) for @entity1 with @entity66 after NAC and RC; (4) choice and indication of chemotherapy regimen if disease continues to progress in @entity1 with advanced @entity150 ; and (5) guidelines used by those surveyed. RESULTS: Consultant uro-oncologists from 77% of UK pelvic @entity5 centers responded, who treated a median of 13 @entity1 per year with NAC before RC. Three cycles of @entity136 and @entity900 was the most common NAC regimen, with 93% and 67% respondents giving it for downstaging of @entity17470 - and @entity18086 - and 3-positive @entity1 , respectively. Forty-five percent would not give AC after NAC and RC in @entity1 with positive lymph nodes. The @entity1 's performance status, followed by response to NAC were key factors in dictating the use of AC. In the presence of disease progression, 46% of @entity1 would use a @entity3907 . Fifty-two percent of responders do not follow any guidelines. CONCLUSION: In the United Kingdom, the treatment of @entity1 with @entity66 after NAC and RC is variable. There is little evidence on which to base the management of such @entity1 . The creation of national and international guidelines might help clinicians to optimize care for these @entity1 .

Management of Node-Positive XXXX After Neoadjuvant Chemotherapy and Radical Cystectomy: A Survey of Current UK Practice.

@entity1 :: ('9606', 'Species') :: ['participants', 'patients', 'patient'] @entity66 :: ('MESH:D004194', 'Disease') :: ['nodal disease'] @entity5 :: ('MESH:D009369', 'Disease') :: ['cancer'] @entity900 :: ('MESH:D002945', 'Chemical') :: ['cisplatin'] @entity3907 :: ('MESH:C080625', 'Chemical') :: ['taxane'] @entity17470 :: ('84618', 'Gene') :: ['cN1'] @entity150 :: ('MESH:D001749', 'Disease') :: ['bladder cancer', 'muscle-invasive bladder cancer'] @entity18086 :: ('55748', 'Gene') :: ['cN2'] @entity136 :: ('MESH:C056507', 'Chemical') :: ['gemcitabine']
@entity150 :: (MESH:D001749,Disease) :: ['Bladder Cancer']
